Physician profile
Brooj Awan
NPI 1558989681
$895.05
in general payments reported to CMS, 2019-2025
12 companies · $329 in 2025
The $329 reported for 2025 was more than what 85% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $567 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $895.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $166.90 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.44 | 2024-2025 | Xifaxan |
| Alexion Pharmaceuticals, INC. | $119.07 | 2024-2025 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $116.67 | 2024-2025 | Terlivaz |
| Janssen Pharmaceuticals, INC | $85.83 | 2024-2025 | Xarelto, Spravato |
| Abbvie INC. | $57.30 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $46.93 | 2024 | Camzyos, Eliquis |
| Ferring Pharmaceuticals INC. | $41.34 | 2024 | Rebyota |
| Teva Pharmaceuticals USA, INC. | $37.77 | 2025 | Austedo Xr |
| Csl Behring | $34.37 | 2024 | Kcentra |
| Eisai INC. | $22.90 | 2024 | |
| Astellas Pharma US INC | $20.53 | 2024 | Cresemba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooj Awan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.